GoodRx (GDRX)
(Real Time Quote from BATS)
$4.32 USD
-0.18 (-4.00%)
Updated Aug 5, 2025 02:54 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GDRX 4.32 -0.18(-4.00%)
Will GDRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GDRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GDRX
Surgery Partners (SGRY) Q2 Earnings and Revenues Beat Estimates
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?
GDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GDRX vs. HQY: Which Stock Is the Better Value Option?
DOCS Boosts Client Retention via Workflow Integration and AI Tools
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx
Other News for GDRX
What To Expect From GoodRx Holdings Inc (GDRX) Q2 2025 Earnings
GoodRx Holdings Inc (GDRX) Appoints Laura Jensen as Chief Commercial Officer | GDRX stock news
GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions | GDRX ...
GoodRx Holdings (GDRX) Shares Cross Above 200 DMA
GoodRx Holdings Inc (GDRX) Announces Q2 2025 Financial Results Release Date | GDRX stock news